Source: Beximco Pharmaceuticals Ltd. (BXPHARMA) | FY 2000-01 | Page 28

Beximco Pharmaceuticals Limited
Cash Flow Statement
Year to 31 December 2001

Amount in Taka

| Particulars | Note | 2001 | 2000 |
|---|---|---|---|
| **Cash Flows from Operating Activities :** | 42 | | |
| Cash Receipts from Customers and Others | | 2,387,968,293 | 2,408,366,414 |
| Cash Paid to Suppliers and Employees | | (1,681,791,740) | (1,841,168,472) |
| **Cash Generated from Operations** | | **706,176,553** | **567,197,942** |
| Interest Paid | | (171,404,878) | (154,363,646) |
| Income Tax Paid & Deducted at Source | | (24,591,042) | (21,097,878) |
| **Net Cash Generated From Operating Activities** | | **510,180,633** | **391,736,418** |
| **Cash Flows from Investing Activities :** | | | |
| Acquisition of Property, Plant and Equipment | | (1,082,771,667) | (314,464,334) |
| Disposal of Property, Plant and Equipment | | 1,207,782 | 4,254,087 |
| Payments for Pre-Production Expenses | | (11,539,017) | (10,575,596) |
| **Net Cash used in Investing Activities** | | **(1,093,102,902)** | **(320,785,843)** |
| **Cash Flows from Financing Activities :** | | | |
| Decrease in Current Account with Related Parties | | 10,464,202 | 3,263,924 |
| Proceeds from Long Term Borrowing | | 656,646,364 | - |
| Cash Credit & other Short Term Loan Received | | 14,196,910 | 82,054,419 |
| Dividend Paid | | (87,129,211) | (153,364,854) |
| **Net Cash Generated / (Used) in Financing Activities** | | **594,178,265** | **(68,046,511)** |
| Net Increase in Cash and Cash Equivalents | | 11,255,996 | 2,904,064 |
| Cash and Cash Equivalents at Begining of Year | | 31,765,405 | 28,861,341 |
| **Cash and Cash Equivalents at End of Year** Tk. |  | **43,021,401** | **31,765,405** |

See accompanying note.

Approved by the board on 29 April 2002 and signed on its behalf by :

C. H. Rahman
Director

Iqbal Ahmed
Director

Md. Asad Ullah
Company Secretary

Dhaka
29 April 2002
Auditors' report is setout alongwith.

Beximco Pharmaceuticals Limited
Accounting Policies and Explanatory Notes
Year to 31 December 2001

The accounting policies and explanatory notes to the financial statements have been set out below in the manner as prescribed by the *IAS 1 "Presentation of Financial Statements"*.

### 1. Corporate Information - Organization and Business

The Beximco Pharmaceuticals Ltd. (the "Company"), a member of BEXIMCO Group, was incorporated in Bangladesh as a public limited company on 17 March 1976. It commenced commercial operation in 1980 and went for public issue of shares in 1985. The shares of the Company are listed in the Dhaka and Chittagong stock exchanges of Bangladesh.

The registered office of the Company is located at House No.17, Road No.2, Dhanmondi Residential Area, Dhaka. The Industrial Units are located at Kathaldia, Auspara, Tongi of Gazipur.

During the year, the principal activities of the company were manufacturing of pharmaceutical drugs and medicines and also basic chemical products and sales thereof. The company employed 1,151 (2000: 1,047), employees as of 31 December 2001.

### 2. Accounting Pronouncements (Standards)

The financial statements of the company have been prepared in accordance with the *International Accounting Standards-IASs* adopted by the *Institute of Chartered Accountants of Bangladesh (ICAB)*, which are basically based on the *International Accounting Standards - IASs* issued by the *International Accounting Standards Committee-IASC* (now replaced by *International Accounting Standards Board - IASB* and *International Accounting Standards Committee Foundation*) and also based on the interpretations issued by the *Standing Interpretations Committee - SIC* (now *International Financial Reporting Interpretations Committee - IFRIC*).

It is noted that, as per the resolution passed by the *IASB*, all the standards to be issued by *IASB* shall be designated as *International Financial Reporting Standards - IFRS* and, all the existing *IASs* issued by *IASC* continue to be applicable and be designated as *IASs* unless and until they are amended or withdrawn.

### 3. Accounting Convention (Measurement Basis)

The financial statements are prepared under the historical cost convention and therefore, do not take into consideration the effect of inflation.

### 4. Basis of Preparation and Presentation of the Financial Statements and The Responsibility Thereto

The board of directors is responsible for the preparation and presentation of financial statements.

The financial statements have been prepared and the disclosures of information have been made in accordance with the requirements of the *Companies Act 1994, the Securities and Exchange Rules 1987, the Listing Rules of Dhaka and Chittagong Stock Exchanges, and the accounting standards referred to in Note 2*.

### 5. Principal Accounting Policies

The specific accounting policies selected and applied by the Company's directors for significant transactions and events that have material effect within the framework of *IAS 1 "Presentation of Financial Statements"*, in preparation and presentation of financial statements have been consistently applied throughout the year and were also consistent with those used in earlier years.

For a proper understanding of the financial statements, these accounting policies are set out below in one place as prescribed by the *IAS 1 "Presentation of Financial Statements"*.